With the global rise of liver diseases, the impact of the TRIF molecule in diverse liver pathologies has gained significant momentum, including viral hepatitis, metabolic dysfunction-associated steatohepatitis (MASH), alcoholic hepatitis, and more. Here, TICAM1 is linked to metabolic dysfunction-associated steatohepatitis.